Jacco de Haan

University of Groningen

Netherlands

Research Interests

Explore related searches

Professors in Netherlands Professors in Cancer Biology Cancer Biology professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (9)

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (3)

Barbara van Munster

NETHERLANDS

View details

Harriët Jager-Wittenaar

Professor of Malnutrition and Healthy Ageing

NETHERLANDS

View details

Rudolf Fehrmann

Tenure track associate professor

University Medical Center Groningen

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jacco de Haan

Research Interests

Explore related searches

Contact this professor

Articles (9)

The relation between preoperative radiological sarcopenia and postoperative recovery of physical activity in older surgical cancer patients; an explorative study

Lessons learned from site-specific sampling and biological half-life of IGFII and IIE(68-88) peptide: a case study

Independent transcriptional patterns reveal biological processes associated with disease-free survival in early colorectal cancer

Subjective Mouthfeel and Temperature Alterations in COVID-19 Patients Six to Ten Months After Diagnosis

Fear of Cancer Recurrence in Sarcoma Survivors: Results from the SURVSARC Study

Taste, smell and mouthfeel disturbances in patients with gastrointestinal stromal tumors treated with tyrosine-kinase inhibitors

Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis

Self-reported taste and smell alterations and the liking of oral nutritional supplements with sensory-adapted flavors in cancer patients receiving systemic antitumor treatment

Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA”

Collaborators (3)

Barbara van Munster

Harriët Jager-Wittenaar

Rudolf Fehrmann

Make your next move.